甲基奎宁环-2-羧酸酯 | 30740-19-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 甲基奎宁环-2-羧酸酯
• 英文名称: quinuclidine-2-carboxylic acid methyl ester
• 英文别名: Chinuclidin-2-carbonsaeure-methylester；2-carbomethoxy-1-azabicyclo[2.2.2]octane；Chinuclidin-2-carbonsaeuremethylester；Methyl quinuclidine-2-carboxylate；methyl 1-azabicyclo[2.2.2]octane-2-carboxylate
• CAS: 30740-19-3
• 化学式: C₉H₁₅NO₂
• 分子量: 169.224
• InChiKey: FAQLMHAFLWKSHD-UHFFFAOYSA-N

物化性质

• 沸点：
  221.5±23.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  甲基奎宁环-2-羧酸酯 在 氨 作用下， 生成 1-aza-bicyclo[2.2.2]octane-2-carboxylic acid amide
  参考文献：
  名称：

  Chinuclidin-Reihe的Untersuchungen。4. Mitteilung。2-Chinuclidin-carbonsäure

  摘要：

  描述了2-喹核苷羧酸的改进的合成。

  DOI：

  10.1002/hlca.19540370723
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 作用下， 生成 甲基奎宁环-2-羧酸酯
  参考文献：
  名称：

  Chinuclidin-Reihe的Untersuchungen。4. Mitteilung。2-Chinuclidin-carbonsäure

  摘要：

  描述了2-喹核苷羧酸的改进的合成。

  DOI：

  10.1002/hlca.19540370723

文献信息

• Physiologically active 1,2,4,-oxa- and thiadiazoles
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US04952587A1

  公开（公告）日：1990-08-28

  The present invention provides a compound of formula I or a salt or prodrug thereof: ##STR1## wherein the dotted circle represents one or two double bonds in any position in the 5-membered ring; X, Y and Z independently represent oxygen, sulphur, nitrogen or carbon, provided that at least one of X, Y and Z represents oxygen, sulphur or nitrogen; A represents a group of formula II: ##STR2## in which R.sup.1 represents hydrogen, hydroxy, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 alkoxy, hydroxy(C.sub.1-6)alkyl, halogen, amino, cyano, --CONR.sup.6 R.sup.7 or --SO.sub.2 NR.sup.6 R.sup.7, in which R.sup.6 and R.sup.7 independently represent hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; R.sup.2 represents hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or C.sub.1-6 alkylcarbonyl; V represents nitrogen, ##STR3## and W represents oxygen, sulphur or ##STR4## in which R.sup.8 represents hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; E represents a bond or a straight or branched alkylene chain containing from 1 to 5 carbon atoms, and optionally being substituted with hydroxy or phenyl; and F represents: (a) a non-aromatic azacyclic or azabicyclic ring system; or (b) a group of formula --NR.sup.a R.sup.b, in which R.sup.a and R.sup.b independently represent hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl or aryl(C.sub.1-6)alkyl; which compounds are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal; pain; gastric stasis; gastric dysfunction (such as occurs with dyspepsia, peptic ulcer, reflux oesophagitis and flatulence); migraine, nausea and vomiting; and presenile and senile dementia.

  本发明提供了化合物I的结构或其盐或前药：其中虚线圆圈代表5-成员环中任意位置的一个或两个双键；X、Y和Z独立地代表氧、硫、氮或碳，但至少一个X、Y和Z代表氧、硫或氮；A代表结构II的一个基团：其中R.sup.1代表氢、羟基、C.sub.1-6烷基、C.sub.2-6烯基、C.sub.2-6炔基、C.sub.1-6烷氧基、羟基(C.sub.1-6)烷基、卤素、氨基、氰基、--CONR.sup.6 R.sup.7或--SO.sub.2 NR.sup.6 R.sup.7，其中R.sup.6和R.sup.7独立地代表氢、C.sub.1-6烷基、C.sub.2-6烯基或C.sub.2-6炔基；R.sup.2代表氢、卤素、C.sub.1-6烷基、C.sub.1-6烷氧基或C.sub.1-6烷基羰基；V代表氮，W代表氧、硫或其中R.sup.8代表氢、C.sub.1-6烷基、C.sub.2-6烯基或C.sub.2-6炔基；E代表键或含有1至5个碳原子的直链或支链烷基链，可选地被羟基或苯基取代；F代表：(a)非芳香性氮杂环或氮杂双环系统；或(b)结构--NR.sup.a R.sup.b的一个基团，其中R.sup.a和R.sup.b独立地代表氢、C.sub.1-6烷基、C.sub.2-6烯基、C.sub.2-6炔基或芳基(C.sub.1-6)烷基；这些化合物在治疗精神分裂症（例如精神分裂症和狂躁症）、焦虑、酒精或药物戒断、疼痛、胃排空延缓、胃功能障碍（如消化不良、消化性溃疡、反流性食道炎和胀气）、偏头痛、恶心呕吐以及老年性痴呆症等方面有用。
• Thiadiazoles useful in the treatment of senile dementia
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0307142A1

  公开（公告）日：1989-03-15

  A class of novel thiadiazoles, substituted on one of the ring carbon atoms with a non-aromatic azacyclic or azabicyclic ring system, and substituted on the other ring carbon atom with a substituent of low lipophilicity, or a hydrocarbon substituent; are potent muscarinic agonists, and have good CNS penetrability. The compounds are therefore useful in the treatment of neurological and mental illnesses, and are also of benefit in the treatment of severe painful conditions.

  一类新型噻二唑，其中一个环碳原子被非芳族氮杂环或氮杂环环系取代，另一个环碳原子被亲脂性低的取代基或烃取代基取代；是强效的毒蕈碱激动剂，具有良好的中枢神经系统穿透性。因此，这些化合物可用于治疗神经和精神疾病，也可用于治疗剧烈疼痛。
• Five-membered ring systems with bonded azacyclic ring substituents
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0328200A1

  公开（公告）日：1989-08-16

  The present invention provides a compound of formula I or a salt or prodrug thereof: wherein the dotted circle represents one or two double bonds in any position in the 5-membered ring; X, Y and Z independently represent oxygen, sulphur, nitrogen or carbon, provided that at least one of X, Y and Z represents oxygen, sulphur or nitrogen; A represents a group of formula II: in which: R' represents hydrogen, hydroxy, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, hydroxy(C1-6)alkyl, halogen, amino, cyano, -CONR6R7 or -S02NR6R7, in which R6 and R7 independently represent hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl; R2 represents hydrogen, halogen, C1 -6 alkyl, C1 -s alkoxy or C1 -6 alkylcarbonyl; V represents nitrogen, - CH or - C -; and W represents oxygen, sulphur or - NR8, in which R8 represents hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl; E represents a bond or a straight or branched alkylene chain containing from 1 to 5 carbon atoms, and optionally being substituted with hydroxy or phenyl; and F represents: . a) a non-aromatic azacyclic or azabicyclic ring system; or b) a group of formula -NRaRb, in which Ra and Rb independently represent hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-s alkynyl or aryl(C1-6)alkyl; which compounds are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal; pain; gastric stasis; gastric dysfunction (such as occurs with dyspepsia, peptic ulcer, reflux oesophagitis and flatulence); migraine, nausea and vomiting; and presenile and senile dementia.

  本发明提供了式 I 的化合物或其盐或原药： 其中圆点代表五元环任意位置上的一个或两个双键； X、Y和Z独立地代表氧、硫、氮或碳，条件是X、Y和Z中至少有一个代表氧、硫或氮； 其中 R'代表氢、羟基、C1-6 烷基、C2-6 烯基、C2-6 炔基、C1-6 烷氧基、羟基（C1-6）烷基、卤素、氨基、氰基、-CONR6R7 或 -S02NR6R7，其中 R6 和 R7 独立地代表氢、C1-6 烷基、C2-6 烯基或 C2-6 烷炔基； R2 代表氢、卤素、C1-6 烷基、C1-s 烷氧基或 C1-6 烷基羰基； V 代表氮、- CH 或 - C -；以及 W 代表氧、硫或- NR8，其中 R8 代表氢、C1-6 烷基、C2-6 烯基或 C2-6 烷炔基； E 代表键或含有 1 至 5 个碳原子的直链或支链亚烷基链，可选择被羟基或苯基取代； 以及 F 代表 a) 非芳氮杂环或氮杂环环系；或 b) 式-NRaRb 的基团，其中 Ra 和 Rb 独立代表氢、C1-6 烷基、C2-6 烯基、C2-s 烷炔基或芳基（C1-6）烷基。这些化合物可用于治疗精神病（如精神分裂症和躁狂症）、焦虑、戒酒或戒毒、疼痛、胃淤血、胃功能障碍（如消化不良、消化性溃疡、反流性食道炎和胀气）、偏头痛、恶心和呕吐以及先天性和老年性痴呆。
• A novel substituted pyrazine, formulations thereof and use in medicine
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0416754A2

  公开（公告）日：1991-03-13

  The compound (R)-3-[2-(6-chloropyrazin)yl]-1-azabicyclo[2.2.2]octane and its salts behave as M₁, M₃ muscarinic agonists and are useful in the treatment of neurological and mental disorders, preferably in a pharmaceutical formulation comprising the active compound in association with a pharmaceutically acceptable carrier. The compound can be prepared by via methods analogous to those known in the art and a chiral acid resolution.

  化合物(R)-3-[2-(6-氯吡嗪)-l]-1-氮杂双环[2.2.2]辛烷及其盐可作为 M₁、M₃ muscarinic 激动剂，可用于治疗神经和精神疾病，优选的药物制剂包括活性化合物与药学上可接受的载体。该化合物可通过类似于本领域已知的方法和手性酸解析法制备。
• Novel 5-HT3 antagonists. Indole oxadiazoles
  作者：C. J. Swain、R. Baker、C. Kneen、J. Moseley、J. Saunders、E. M. Seward、G. Stevenson、M. Beer、J. Stanton、K. Watling

  DOI：10.1021/jm00105a021

  日期：1991.1

  The synthesis and biochemical evaluation of a series of indole oxadiazole 5-HT3 antagonists are described. The key pharmacophoric elements have been defined as a basic nitrogen, a linking group capable of H-bonding interactions, and an aromatic moiety. The steric limitations of the aromatic binding site have been determined by substitution about the indole ring. Variation of the heterocyclic linking group has shown that while two hydrogen-bonding interactions are possible, only one is essential for high affinity. The environment of the basic nitrogen has been investigated and shown to be optimal when constrained within an azabicyclic system. These results have been incorporated into a proposed binding model for the 5-HT3 antagonist binding site, in which the optimum distance between the aromatic binding site and the basic amine is 8.4-8.9 angstrom and the steric limitations are defined by van der Waals difference mapping.